Aliases & Classifications for Mammographic Density

MalaCards integrated aliases for Mammographic Density:

Name: Mammographic Density 57 73

External Ids:

OMIM 57 607308
UMLS 73 C1846502

Summaries for Mammographic Density

MalaCards based summary : Mammographic Density is related to ductal carcinoma in situ and insulin-like growth factor i. An important gene associated with Mammographic Density is IGF1 (Insulin Like Growth Factor 1), and among its related pathways/superpathways are Cytochrome P450 - arranged by substrate type and Glucose / Energy Metabolism. The drugs Drospirenone and Estradiol valerate have been mentioned in the context of this disorder. Affiliated tissues include breast and bone, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Description from OMIM: 607308

Related Diseases for Mammographic Density

Diseases related to Mammographic Density via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 132)
# Related Disease Score Top Affiliating Genes
1 ductal carcinoma in situ 29.9 CYP19A1 ESR1 PGR
2 insulin-like growth factor i 29.7 ESR1 IGF1 IGFBP3 PRL
3 breast disease 26.1 COMT CYP1A1 CYP1B1 ESR1 IGF1 IGFBP3
4 breast cancer 25.9 CYP17A1 CYP19A1 CYP1A1 CYP1B1 ESR1 IGF1
5 slipped capital femoral epiphysis 10.8 IGF1 IGFBP3
6 secondary adrenal insufficiency 10.8 IGF1 IGFBP3
7 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.8 IGF1 IGFBP3
8 diffuse idiopathic skeletal hyperostosis 10.8 IGF1 IGFBP3
9 central precocious puberty 10.8 IGF1 IGFBP3
10 galactorrhea 10.8 IGF1 PRL
11 pituitary infarct 10.8 IGF1 PRL
12 pseudohypoparathyroidism, type ia 10.7 IGF1 PRL
13 isolated growth hormone deficiency, type ib 10.7 IGF1 IGFBP3
14 empty sella syndrome 10.7 IGF1 PRL
15 acid-labile subunit deficiency 10.7 IGF1 IGFBP3
16 sheehan syndrome 10.7 IGF1 PRL
17 schizophreniform disorder 10.7 COMT PRL
18 hypothyroidism, congenital, nongoitrous, 4 10.7 IGF1 PRL
19 central nervous system organ benign neoplasm 10.6 IGF1 PRL
20 fibromyalgia 10.6 COMT IGF1
21 traumatic brain injury 10.6 COMT IGF1
22 fetal macrosomia 10.6 IGF1 IGFBP3
23 endometrial disease 10.5 CYP19A1 ESR1
24 testicular leydig cell tumor 10.5 CYP17A1 ESR1
25 aromatase deficiency 10.5 CYP19A1 ESR1
26 vulvar syringoma 10.5 ESR1 PGR
27 lung leiomyoma 10.5 ESR1 PGR
28 vestibular gland benign neoplasm 10.5 ESR1 PGR
29 bartholin's gland adenoma 10.5 ESR1 PGR
30 glassy cell carcinoma of the cervix 10.5 ESR1 PGR
31 penis agenesis 10.5 CYP17A1 IGFBP3
32 vulvar benign neoplasm 10.5 ESR1 PGR
33 trigonitis 10.5 ESR1 PGR
34 vulvar leiomyoma 10.5 ESR1 PGR
35 complete androgen insensitivity syndrome 10.4 CYP19A1 IGFBP3
36 predominantly cortical thymoma 10.4 ESR1 PGR
37 breast medullary carcinoma 10.4 ESR1 PGR
38 breast scirrhous carcinoma 10.4 ESR1 PGR
39 progesterone resistance 10.4 ESR1 PGR
40 cribriform carcinoma 10.4 ESR1 PGR
41 oncocytic breast carcinoma 10.4 ESR1 PGR
42 endometrial squamous cell carcinoma 10.4 ESR1 PGR
43 gastric signet ring cell adenocarcinoma 10.4 ESR1 PGR
44 androgenic alopecia 10.4 CYP19A1 PRL
45 endometrial mucinous adenocarcinoma 10.4 ESR1 PGR
46 adenoid basal cell carcinoma 10.4 ESR1 PGR
47 apocrine adenocarcinoma 10.4 ESR1 PGR
48 bartholin's gland benign neoplasm 10.4 ESR1 PGR
49 laron syndrome 10.4 IGF1 IGFBP3
50 deep angioma 10.4 ESR1 PGR

Graphical network of the top 20 diseases related to Mammographic Density:



Diseases related to Mammographic Density

Symptoms & Phenotypes for Mammographic Density

Clinical features from OMIM:

607308

MGI Mouse Phenotypes related to Mammographic Density:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.02 COMT IGF1 CYP17A1 IGFBP3 CYP19A1 PGR
2 endocrine/exocrine gland MP:0005379 9.97 COMT IGF1 IGFBP3 CYP19A1 PGR CYP1A1
3 cardiovascular system MP:0005385 9.95 ESR1 COMT IGF1 IGFBP3 CYP19A1 PGR
4 adipose tissue MP:0005375 9.83 ESR1 IGF1 CYP17A1 IGFBP3 CYP19A1
5 integument MP:0010771 9.73 PRL ESR1 IGF1 IGFBP3 CYP19A1 PGR
6 neoplasm MP:0002006 9.55 PRL ESR1 IGF1 PGR CYP1B1
7 renal/urinary system MP:0005367 9.43 ESR1 COMT IGF1 CYP17A1 IGFBP3 CYP19A1
8 reproductive system MP:0005389 9.17 PRL ESR1 COMT IGF1 CYP17A1 CYP19A1

Drugs & Therapeutics for Mammographic Density

Drugs for Mammographic Density (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Drospirenone Approved Phase 4 67392-87-4 68873
2 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 979-32-8
3
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 50-28-2 5757
4
Polyestradiol phosphate Approved Phase 4,Phase 2,Not Applicable 28014-46-2
5 Contraceptive Agents Phase 4,Not Applicable
6 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Estradiol 17 beta-cypionate Phase 4,Phase 2,Not Applicable
10 Estradiol 3-benzoate Phase 4,Phase 2,Not Applicable
11 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Estrogens, Conjugated (USP) Phase 4,Not Applicable
13
Tamoxifen Approved Phase 3,Phase 2,Not Applicable 10540-29-1 2733526
14
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 1406-16-2
15
Ergocalciferol Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 50-14-6 5280793
16
Afimoxifene Investigational Phase 3,Phase 2 68392-35-8
17 Selective Estrogen Receptor Modulators Phase 3,Phase 2,Not Applicable
18 Estrogen Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
19 Estrogen Receptor Modulators Phase 3,Phase 2,Not Applicable
20 Bone Density Conservation Agents Phase 3,Phase 2,Phase 1,Not Applicable
21 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Not Applicable
22 Micronutrients Phase 3,Phase 2,Phase 1,Not Applicable
23 Trace Elements Phase 3,Phase 2,Phase 1,Not Applicable
24 Ergocalciferols Phase 3,Phase 2,Phase 1,Not Applicable
25 Vitamins Phase 3,Phase 2,Phase 1,Not Applicable
26 Vitamin D2 Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable
27 Calciferol Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable
28
Metformin Approved Phase 2,Phase 1 657-24-9 14219 4091
29
Fulvestrant Approved, Investigational Phase 2,Not Applicable 129453-61-8 104741 17756771
30
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
31
Exemestane Approved, Investigational Phase 2 107868-30-4 60198
32
Tibolone Approved, Investigational Phase 2 5630-53-5
33
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
34
Calcium Carbonate Approved, Investigational Phase 2 471-34-1
35
Lovastatin Approved, Investigational Phase 2 75330-75-5 53232
36
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2,Not Applicable 77-92-9 311
37
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 2 83-88-5 493570
38
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
39
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
40
Epigallocatechin gallate Investigational Phase 2,Phase 1 989-51-5 65064
41 Atorvastatin Calcium Phase 2 134523-03-8
42 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
43 Hypoglycemic Agents Phase 2,Phase 1
44 Hypolipidemic Agents Phase 2
45 Estrogen Receptor Antagonists Phase 2,Not Applicable
46 Anticholesteremic Agents Phase 2
47 Lipid Regulating Agents Phase 2
48 Antimetabolites Phase 2
49 Calcium, Dietary Phase 2,Phase 1
50 Analgesics Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 Effects of Estradiol on Menopausal Breast Unknown status NCT00785317 Phase 4 Angemin vs Activelle
2 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
3 Breast Cancer Screening With MRI in Women Aged 50-75 Years With Extremely Dense Breast Tissue: the DENSE Trial Active, not recruiting NCT01315015 Phase 4
4 Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women Unknown status NCT00808522 Phase 3 hCG
5 Vitamin D and Breast Cancer Biomarkers in Female Patients Completed NCT01224678 Phase 3
6 Trial of 4-OHT Gel in Women Aimed at Reducing Dense Breast Tissue Recruiting NCT03199963 Phase 3 4-OH tamoxifen;Placebo gel
7 Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia Active, not recruiting NCT01357772 Phase 3 Tamoxifen;placebo
8 Statins and Breast Cancer Biomarkers Unknown status NCT00914017 Phase 2 Atorvastatin;Placebo
9 Green Tea and Reduction of Breast Cancer Risk Completed NCT00917735 Phase 2 Green tea extract supplement
10 Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer Completed NCT00073073 Phase 2 Exemestane
11 Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy Completed NCT00165204 Phase 2 Tibolone
12 Study of Breast Cancer Prevention by Letrozole in High Risk Women Completed NCT00579826 Phase 2 Letrozole;Placebo
13 Protocol for Women at Increased Risk of Developing Breast Cancer Completed NCT00291694 Phase 2 celecoxib
14 Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer Completed NCT00853996 Phase 2 acolbifene hydrochloride
15 Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast Recruiting NCT03063619 Phase 2 Afimoxifene
16 Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer Recruiting NCT01589367 Phase 2 Metformin;Placebo
17 Soy Isoflavones and Breast Cancer Risk Reduction Active, not recruiting NCT00204490 Phase 2
18 Soy Protein and Breast Cancer Risk Reduction Active, not recruiting NCT00204477 Phase 2
19 Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors Active, not recruiting NCT01196936 Phase 2 Tamoxifen Citrate;Placebo
20 Karma Intervention Study Enrolling by invitation NCT03346200 Phase 2 Tamoxifen Oral Tablet;Placebo Oral Tablet
21 S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women Terminated NCT00088972 Phase 2 celecoxib
22 A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS) Terminated NCT00183963 Phase 2 Tamoxifen;Fulvestrant;Fulvestrant
23 Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention Terminated NCT00285857 Phase 2 Lovastatin
24 Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density Completed NCT03264651 Phase 1 enobosarm
25 A Single Dose Trial to Evaluate the Pharmacokinetics of Testosterone and Anastrozole Completed NCT03314298 Phase 1 testosterone anastrozole
26 Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer Completed NCT00976339 Phase 1 Cholecalciferol
27 Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer Completed NCT00516243 Phase 1 defined green tea catechin extract
28 Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission Recruiting NCT02780401 Phase 1
29 Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer Active, not recruiting NCT02278965 Phase 1 Metformin;Omega-3 fatty acids
30 Studying Changes in Breast Density in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride or Placebo on CAN-NCIC-MA.32 Unknown status NCT01666171 metformin hydrochloride
31 Radiologic Evaluation and Breast Density (READ) Unknown status NCT00117663 Not Applicable Cessation of Hormone Replacement Therapy
32 Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast Unknown status NCT00126464 Not Applicable fulvestrant;tamoxifen citrate
33 Brazilian Randomized Study - Impact of MRI for Breast Cancer Unknown status NCT02798796 Not Applicable
34 KEEPS Mammographic Density And Breast Health Ancillary Study Completed NCT02524561 Not Applicable CEE pill;Estradiol patch;Active Progesterone
35 Mammographic Density and the Risk of Tumor Recurrence in Asian Women: a Case-control Study Completed NCT02771665
36 Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Rlisk Completed NCT00839696
37 Study Evaluating Changes In Mammographic Breast Density Completed NCT00774267 BZA 20 mg/CE 0.45 mg;BZA 20 mg/CE 0.625 mg;Raloxifene 60 mg;Placebo
38 Effect of Aspirin on Mammogram Density in Healthy Postmenopausal Women With a Moderate or High Level of Breast Density Completed NCT00470561 Not Applicable Aspirin;Placebo
39 Genetics of Mammographic Appearances and Patterns (The GenMap Study) Completed NCT01160510
40 Vitamin D and Mammographic Breast Density Completed NCT01747720 Not Applicable
41 Histology of Functional Density in Premenopausal Breast Completed NCT01588834
42 Breast Cancer, Breast Disease, and Pesticides Completed NCT00341315
43 Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density Completed NCT00418236
44 Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study Completed NCT00006425
45 S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer Completed NCT01097278 Not Applicable
46 Zoladex Plus Tamoxifen in Breast Cancer Completed NCT00827307 Not Applicable tamoxifen;Goserelin
47 Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D Completed NCT01166763 Not Applicable vitamin D3
48 Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial Completed NCT00522262 Not Applicable
49 Third Year Evaluation on Genistein Efficacy and Safety Completed NCT00626769
50 Diindolylmethane in Treating Patients With Breast Cancer Completed NCT01391689 Not Applicable

Search NIH Clinical Center for Mammographic Density

Genetic Tests for Mammographic Density

Anatomical Context for Mammographic Density

MalaCards organs/tissues related to Mammographic Density:

41
Breast, Bone

Publications for Mammographic Density

Articles related to Mammographic Density:

(show top 50) (show all 122)
# Title Authors Year
1
A comprehensive tool for measuring mammographic density changes over time. ( 29392583 )
2018
2
Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction. ( 29346471 )
2018
3
Should breast cancer screening programs routinely measure mammographic density? ( 29624213 )
2018
4
The origins of breast cancer associated with mammographic density: a testable biological hypothesis. ( 29514672 )
2018
5
Breast cancer risk factors and mammographic density among high-risk women in urban China. ( 29423438 )
2018
6
Automated Volumetric Analysis of Mammographic Density in a Screening Setting: Worse Outcomes for Women with Dense Breasts. ( 29944088 )
2018
7
Prenatal diethylstilbestrol exposure and mammographic density. ( 29658110 )
2018
8
Hormone replacement therapy, mammographic density, and breast cancer risk: a cohort study. ( 29671181 )
2018
9
Mammographic density and breast cancer risk in breast screening assessment cases and women with a family history of breast cancer. ( 29190506 )
2018
10
Exploring the prediction performance for breast cancer risk based on volumetric mammographic density at different thresholds. ( 29884207 )
2018
11
Circulating Hormones and Mammographic Density in Premenopausal Women. ( 29330698 )
2018
12
Alcohol consumption across the life course and mammographic density in premenopausal women. ( 28952004 )
2018
13
Adiposity at Age 10 and Mammographic Density among Premenopausal Women. ( 29500187 )
2018
14
Mammographic Density Distribution in Ras Al Khaimah (RAK): Relationships with Demographic and Reproductive Factors ( 29936786 )
2018
15
Breast Cancer Risk Associations with Digital Mammographic Density by Pixel Brightness Threshold and Mammographic System. ( 29040039 )
2018
16
Mammographic density changes in surgical weight loss-an indication for personalized screening. ( 29743035 )
2018
17
Serum osteoprotegerin levels and mammographic density among high-risk women. ( 29679262 )
2018
18
Occupational exposures and mammographic density in Spanish women. ( 29074552 )
2018
19
Volumetric mammographic density, age-related decline, and breast cancer risk factors in a national breast cancer screening program. ( 29925631 )
2018
20
Common genetic variation and novel loci associated with volumetric mammographic density. ( 29665850 )
2018
21
Mammographic density changes following discontinuation of tamoxifen in premenopausal women with oestrogen receptor-positive breast cancer. ( 29626240 )
2018
22
A comparison of five methods of measuring mammographic density: a case-control study. ( 29402289 )
2018
23
The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study. ( 29566728 )
2018
24
An overview of mammographic density and its association with breast cancer. ( 29651637 )
2018
25
Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics. ( 29502324 )
2018
26
T<sub>1</sub>-based sensing of mammographic density using single-sided portable NMR. ( 29399874 )
2018
27
Breast compression parameters and mammographic density in the Norwegian Breast Cancer Screening Programme. ( 29098437 )
2017
28
Comparison of the association of mammographic density and clinical factors with ductal carcinoma in situ versus invasive ductal breast cancer in Korean women. ( 29207971 )
2017
29
Mammographic density and risk of breast cancer by tumor characteristics: a case-control study. ( 29246131 )
2017
30
Alcohol consumption and mammographic density in the Danish Diet, Cancer and Health cohort. ( 28965165 )
2017
31
Mammographic density and other risk factors for breast cancer among women in China. ( 29193600 )
2017
32
Residential particulate matter and distance to roadways in relation to mammographic density: results from the Nurses' Health Studies. ( 29169389 )
2017
33
The Association of Mammographic Density and Molecular Breast Cancer Subtype. ( 28698184 )
2017
34
Association between mammographic density and tumor marker-defined breast cancer subtypes: a case-control study. ( 28957821 )
2017
35
Tumor characteristics and family history in relation to mammographic density and breast cancer: The French E3N cohort. ( 28697417 )
2017
36
Increased breast tissue receptor activator of nuclear factor-I_B ligand (RANKL) gene expression is associated with higher mammographic density in premenopausal women. ( 29088745 )
2017
37
Mammographic density and associated predictive factors for Chinese women. ( 29178368 )
2017
38
Routine reporting of mammographic density from screening mammograms. ( 29205822 )
2017
39
Association of Catechol-O-methyltransferase polymorphism Val158Met and mammographic density: A meta-analysis. ( 28473194 )
2017
40
Childhood body mass index and adult mammographic density measures that predict breast cancer risk. ( 26907766 )
2016
41
A statistical model of breast cancer tumour growth with estimation of screening sensitivity as a function of mammographic density. ( 23839121 )
2016
42
Polymorphisms in the estrogen receptor alpha gene (ESR1), daily cycling estrogen and mammographic density phenotypes. ( 27717337 )
2016
43
Mammographic density defined by higher than conventional brightness threshold better predicts breast cancer risk for full-field digital mammograms. ( 26581435 )
2015
44
Association between high-sensitivity C-reactive protein (hsCRP) and change in mammographic density over time in the SWAN mammographic density subcohort. ( 25604866 )
2015
45
Novel associations between common breast cancer susceptibility variants and risk-predicting mammographic density measures. ( 25862352 )
2015
46
Genome wide association study identifies a novel putative mammographic density locus at 1q12-q21. ( 25353672 )
2015
47
Breast Tissue Composition and Immunophenotype and Its Relationship with Mammographic Density in Women at High Risk of Breast Cancer. ( 26110820 )
2015
48
Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. ( 26627479 )
2015
49
Identification of two novel mammographic density loci at 6Q25.1. ( 26036842 )
2015
50
Volumetric mammographic density: heritability and association with breast cancer susceptibility Loci. ( 25376863 )
2014

Variations for Mammographic Density

Expression for Mammographic Density

Search GEO for disease gene expression data for Mammographic Density.

Pathways for Mammographic Density

Pathways related to Mammographic Density according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.96 COMT CYP17A1 CYP19A1 CYP1A1 CYP1B1 UGT1A1
2 12.3 CYP17A1 CYP19A1 IGFBP3 UGT1A1
3
Show member pathways
11.97 CYP19A1 CYP1A1 CYP1B1
4
Show member pathways
11.73 ESR1 PGR PRL
5
Show member pathways
11.46 CYP1A1 CYP1B1 UGT1A1
6 11.29 CYP1A1 CYP1B1 ESR1
7
Show member pathways
11.29 COMT CYP17A1 CYP19A1 CYP1A1
8 11.26 CYP1A1 CYP1B1 UGT1A1
9 11.24 CYP17A1 CYP19A1 CYP1A1 CYP1B1 IGF1
10 11.14 CYP1A1 CYP1B1
11 11.06 CYP19A1 PGR
12
Show member pathways
10.92 CYP1A1 CYP1B1 UGT1A1
13
Show member pathways
10.91 COMT CYP17A1 CYP19A1 CYP1A1 CYP1B1 UGT1A1
14
Show member pathways
10.89 COMT CYP19A1 CYP1A1 CYP1B1 UGT1A1
15 10.86 IGF1 IGFBP3
16 10.61 CYP1A1 CYP1B1 ESR1
17 10.06 CYP19A1 ESR1

GO Terms for Mammographic Density

Cellular components related to Mammographic Density according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum membrane GO:0005789 9.55 CYP17A1 CYP19A1 CYP1A1 CYP1B1 UGT1A1
2 insulin-like growth factor ternary complex GO:0042567 8.96 IGF1 IGFBP3
3 insulin-like growth factor binding protein complex GO:0016942 8.62 IGF1 IGFBP3

Biological processes related to Mammographic Density according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.76 IGF1 IGFBP3 PRL
2 response to lipopolysaccharide GO:0032496 9.74 COMT CYP1A1 UGT1A1
3 response to organic cyclic compound GO:0014070 9.65 COMT CYP1A1 UGT1A1
4 response to organic substance GO:0010033 9.61 CYP1A1 IGF1 UGT1A1
5 developmental process GO:0032502 9.6 COMT CYP1A1
6 cellular response to estradiol stimulus GO:0071392 9.59 ESR1 UGT1A1
7 negative regulation of smooth muscle cell proliferation GO:0048662 9.58 COMT IGFBP3
8 regulation of multicellular organism growth GO:0040014 9.56 IGF1 PRL
9 positive regulation of JAK-STAT cascade GO:0046427 9.55 CYP1B1 PRL
10 drug metabolic process GO:0017144 9.54 CYP1A1 UGT1A1
11 epoxygenase P450 pathway GO:0019373 9.52 CYP1A1 CYP1B1
12 androgen metabolic process GO:0008209 9.51 CYP19A1 ESR1
13 uterus development GO:0060065 9.49 CYP19A1 ESR1
14 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.46 IGF1 IGFBP3
15 mammary gland development GO:0030879 9.43 CYP19A1 PGR PRL
16 omega-hydroxylase P450 pathway GO:0097267 9.4 CYP1A1 CYP1B1
17 toxin metabolic process GO:0009404 9.37 CYP1A1 CYP1B1
18 sterol metabolic process GO:0016125 9.33 CYP17A1 CYP19A1 CYP1B1
19 heterocycle metabolic process GO:0046483 9.32 CYP1A1 UGT1A1
20 steroid metabolic process GO:0008202 9.26 CYP17A1 CYP1A1 CYP1B1 UGT1A1
21 estrogen metabolic process GO:0008210 8.8 COMT CYP1B1 UGT1A1

Molecular functions related to Mammographic Density according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.81 CYP17A1 CYP19A1 CYP1A1 CYP1B1
2 enzyme binding GO:0019899 9.76 CYP1A1 ESR1 PGR UGT1A1
3 iron ion binding GO:0005506 9.71 CYP17A1 CYP19A1 CYP1A1 CYP1B1
4 heme binding GO:0020037 9.62 CYP17A1 CYP19A1 CYP1A1 CYP1B1
5 monooxygenase activity GO:0004497 9.61 CYP19A1 CYP1A1 CYP1B1
6 steroid binding GO:0005496 9.54 ESR1 PGR UGT1A1
7 steroid hydroxylase activity GO:0008395 9.49 CYP19A1 CYP1A1
8 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.43 CYP19A1 CYP1A1 CYP1B1
9 aromatase activity GO:0070330 9.33 CYP19A1 CYP1A1 CYP1B1
10 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.26 CYP17A1 CYP19A1 CYP1A1 CYP1B1
11 oxygen binding GO:0019825 8.92 CYP17A1 CYP19A1 CYP1A1 CYP1B1
12 metal ion binding GO:0046872 10.08 COMT CYP17A1 CYP19A1 CYP1A1 CYP1B1 ESR1

Sources for Mammographic Density

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....